SCYNEXIS Receives Milestone Payment in Oncology Collaboration with Merck & Co., Inc.

RESEARCH TRIANGLE PARK, N.C.--(Business Wire)--
Drug discovery companySCYNEXIS, Inc. today announced that it has received a
payment from Merck & Co., Inc. for achieving a preclinical milestone resulting
from a collaboration to discover and develop novel oncology agents.

"We are pleased to celebrate success in reaching another milestone with our
valued partner, Merck," said Yves Ribeill, Ph.D., President and Chief Executive
Officer of SCYNEXIS. "This milestone provides further validation of our
long-term relationship with Merck in a number of therapeutic areas through
discovery research and innovation."

About SCYNEXIS

SCYNEXIS is a premier drug discovery and development company headquartered in
Research Triangle Park, North Carolina. SCYNEXIS` mission is to be the leader in
delivering effective and innovative drug pipeline solutions to its
pharmaceutical partners.

SCYNEXIS research teams integrate medicinal chemistry, advanced biological
screening, computational chemistry, bioanalysis and analytical chemistry and use
powerful, proprietary technologies such as the HEOS Software Suite and
MEDCHEM-FACTORY to advance molecules to candidate selection. SCYNEXIS
development teams have been tailored to be especially effective in moving
customer projects from the discovery phase to the clinic. SCYNEXIS process
chemistry and bioanalytical departments operate under current GMP/GLP guidelines
and have a strong track record of success. SCYNEXIS is registered with both the
FDA and DEA. www.scynexis.com

Company Contact:
SCYNEXIS, Inc.
Terry Marquardt, 919-544-8600
Terry.Marquardt@scynexis.com
or
Media Relations:
Rick Rountree Communications
Rick Rountree
rick@rickrountree.com
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 781-235-3060
scavanaugh@macbiocom.com

Copyright Business Wire 2009